Plain-English translation of NCT04417387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The GENVASC study is testing whether genetic information can improve the way doctors predict heart disease risk. Right now, doctors use factors like age, smoking, and blood pressure to estimate risk, but many heart attacks still happen in people classified as low or medium risk. This study wants to see if adding a simple genetic test can help identify at-risk people more accurately.
Heart disease is the leading cause of early death and disability in the UK. Current risk prediction tools miss many people who will actually develop heart disease because family history is often unreliable and doesn't capture your true genetic risk. This study exists to find out whether genetic testing could be a better, more accurate way to predict who really needs preventive treatment.
You likely qualify if…
You likely don't qualify if…
As a participant, you would likely provide a blood sample for genetic testing as part of a routine NHS Health Check appointment. The study is still recruiting, so the exact details of visits and follow-up are not fully specified, but your genetic information would be used to see whether it improves heart disease risk prediction compared to current methods.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United Kingdom
Collaborators
University Hospitals, Leicester
Enrollment target
~30,000 participants
Started
September 2012
Primary completion
March 2027
Age range
40 Years – 74 Years
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Emma P Beeston
NIHR Leicester Biomedical Research Centre-Cardiovascular Theme
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.